The Board of Directors of the Company in its meeting held today i.e., May 07, 2026 has approved the equity infusion in Think Health Diagnostics Private Limited (Wholly Owned Subsidiary)
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare's Board approved an equity infusion of up to Rs. 5.5 crore into its wholly owned subsidiary, Think Health Diagnostics Private Limited, to support its capital expenditure and working capital requirements. Think Health is building an affordable diagnostics platform focused on high-volume testing like thyroid and routine pathology. The subsidiary reported minimal turnover of Rs. 0.01 crore for FY 2025-26, down from Rs. 3.35 crore in FY 2023-24, indicating it is in early stages. This is a related party transaction being done at arm's length. The Board also recommended a final dividend of Rs. 7 per share (total Rs. 9.33 per share post-bonus), appointed Price Waterhouse as new statutory auditors, re-appointed its CEO for 5 years, and added two new directors while two directors resigned.
The equity infusion signals Thyrocare's continued commitment to its subsidiary despite declining revenues, reflecting confidence in the diagnostics platform's potential. The broader board changes and dividend recommendation indicate stable governance, but investors should note the subsidiary's early-stage nature with uncertain revenue trajectory.